close

Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs. The company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It distributes the branded version of oxandrolone in the United States, under the name Oxandrin and authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. The company also involves in developing KRYSTEXXA (pegloticase), a biologic PEGylated uricase enzyme to control hyperuricemia, and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning, and decreased frequency of flares for patients with treatment-failure gout. It distributes its products through wholesalers. The company, formerly known as Bio-Technology General Corp., was founded in 1980 and is headquartered in East Brunswick, New Jersey.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.93
Volume	707894
Volume Avg	(mio) 1.45
52 Week High	11.91
52 Week Low	1.82
PE	N/A
PE (group average)	39
EPS Year	-1.46
EPS change Q/Q	-1800%
EPS change Q/Q Yr ago	-46.15%
EPS change Q/Q next Q est	-57.78%
EPS change Y/Y	-10.34%
REV change Q/Q	30%
REV change Q/Q Yr ago	18.18%
EPS next Q est	-0.45
EPS next Y est	-1.07
Divident Annual	0.00
Dividend Yield	0%